Atsushi Horiike, Hiroshi Wakui, Shunichi Sugawara, Yuji Minegishi, Sadatomo Tasaka, Toshio Sakatani, Hiroyuki Suzuki, Yukio Hosomi, Yuichi Tambo, Tsuneo Shimokawa, Hiroo Ishida, Eisaku Miyauchi, Katsuhiko Naoki, Tatsuro Fukuhara, Sachiko Takenoshita, Eisuke Inoue, Satoshi Wada, Kiyoshi Yoshimura, Shinichi Kobayashi, Takuya Tsunoda. "Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1–high advanced NSCLC: Final results of the phase II K-TAIL-202 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.8573